Loading grant details…
Targeted Degradation of HIV Integrase as a Novel Treatment of Infection
| Funder | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES |
|---|---|
| Recipient Organization | Xavier University of Louisiana |
| Country | United States |
| Start Date | Aug 05, 2024 |
| End Date | Jun 30, 2026 |
| Duration | 694 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10953006 |
Grant Description
Targeted Degradation of HIV Integrase as a Novel Treatment of Infection PROJECT SUMMARY Due to the development of antiretroviral therapy, HIV-1 infection is no longer a death sentence but rather a treatable chronic disease, providing people with HIV an almost normal life expectancy. However, the most recent
WHO HIV Drug Resistance Report indicates that the prevalence of acquired and transmitted HIV drug resistance has exponentially increased in the recent years. The prevalence of three and four-class resistant HIV is already estimated to range from 5 to 10% in Europe, while somewhat lower rates are still reported for North America
(
All Grantees
Xavier University of Louisiana
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
